Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2016, Article ID 6383240, 16 pages
http://dx.doi.org/10.1155/2016/6383240
Research Article

Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson’s Disease

1Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, China
2Suqian First Hospital, Suqian, Jiangsu 223800, China
3Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215123, China
4Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, Jiangsu 215123, China

Received 21 April 2016; Accepted 29 August 2016

Academic Editor: Preston E. Garraghty

Copyright © 2016 Lei-Fang Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. V. Kalia and A. E. Lang, “Parkinson's disease,” The Lancet, vol. 386, no. 9996, pp. 896–912, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. E. C. Hirsch, P. Jenner, and S. Przedborski, “Pathogenesis of Parkinson's disease,” Movement Disorders, vol. 28, no. 1, pp. 24–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. M. Dawson and V. L. Dawson, “Molecular pathways of neurodegeneration in Parkinson's disease,” Science, vol. 302, no. 5646, pp. 819–822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Fasano, A. Daniele, and A. Albanese, “Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation,” The Lancet Neurology, vol. 11, no. 5, pp. 429–442, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S.-Y. Lim and A. E. Lang, “The nonmotor symptoms of Parkinson's disease—an overview,” Movement Disorders, vol. 25, supplement 1, pp. S123–S130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” The Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. C. H. Adler and T. G. Beach, “Neuropathological basis of nonmotor manifestations of Parkinson's disease,” Movement Disorders, vol. 31, no. 8, pp. 1114–1119, 2016. View at Publisher · View at Google Scholar
  9. G. Defazio, A. Berardelli, G. Fabbrini et al., “Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study,” Archives of Neurology, vol. 65, no. 9, pp. 1191–1194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Antonini, P. Barone, R. Marconi et al., “The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life,” Journal of Neurology, vol. 259, no. 12, pp. 2621–2631, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Borsook, “Neurological diseases and pain,” Brain, vol. 135, part 2, pp. 320–344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. G. Beiske, J. H. Loge, A. Rønningen, and E. Svensson, “Pain in Parkinson's disease: prevalence and characteristics,” Pain, vol. 141, no. 1-2, pp. 173–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Ford, “Pain in Parkinson's disease,” Movement Disorders, vol. 25, supplement 1, pp. S98–S103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C.-J. Mao, J.-P. Chen, X.-Y. Zhang et al., “Parkinson’s disease patients with pain suffer from more severe non-motor symptoms,” Neurological Sciences, vol. 36, no. 2, pp. 263–268, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Dellapina, F. Ory-Magne, W. Regragui et al., “Effect of subthalamic deep brain stimulation on pain in Parkinson's disease,” Pain, vol. 153, no. 11, pp. 2267–2273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. H.-J. Kim, B. S. Jeon, and S. H. Paek, “Effect of deep brain stimulation on pain in Parkinson disease,” Journal of the Neurological Sciences, vol. 310, no. 1-2, pp. 251–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. J. Kim, B. S. Jeon, and S. H. Paek, “Nonmotor symptoms and subthalamic deep brain stimulation in Parkinson's disease,” Journal of Movement Disorders, vol. 8, no. 2, pp. 83–91, 2015. View at Google Scholar
  18. A. Fil, R. Cano-de-la-Cuerda, E. Muñoz-Hellín, L. Vela, M. Ramiro-González, and C. Fernández-de-las-Peñas, “Pain in Parkinson disease: a review of the literature,” Parkinsonism and Related Disorders, vol. 19, no. 3, pp. 285–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. D. F. Drake, S. Harkins, and A. Qutubuddin, “Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation,” NeuroRehabilitation, vol. 20, no. 4, pp. 335–341, 2005. View at Google Scholar · View at Scopus
  20. A. Antonini and M. Tinazzi, “Targeting pain in Parkinson's disease,” The Lancet Neurology, vol. 14, no. 12, pp. 1144–1145, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. DeLong and T. Wichmann, “Basal ganglia circuits as targets for neuromodulation in Parkinson disease,” JAMA Neurology, vol. 72, no. 11, pp. 1354–1360, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Barker, “The basal ganglia and pain,” International Journal of Neuroscience, vol. 41, no. 1-2, pp. 29–34, 1988. View at Publisher · View at Google Scholar · View at Scopus
  23. E. H. Chudler and W. K. Dong, “The role of the basal ganglia in nociception and pain,” Pain, vol. 60, no. 1, pp. 3–38, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Buddhala, S. K. Loftin, B. M. Kuley et al., “Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease,” Annals of Clinical and Translational Neurology, vol. 2, no. 10, pp. 949–959, 2015. View at Publisher · View at Google Scholar
  25. A. Castrioto, S. Thobois, S. Carnicella, A. Maillet, and P. Krack, “Emotional manifestations of PD: Neurobiological basis,” Movement Disorders, vol. 31, no. 8, pp. 1103–1113, 2016. View at Publisher · View at Google Scholar
  26. F. Fornai, A. B. di Poggio, A. Pellegrini, S. Ruggieri, and A. Paparelli, “Noradrenaline in Parkinson's disease: from disease progression to current therapeutics,” Current Medicinal Chemistry, vol. 14, no. 22, pp. 2330–2334, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Briley, “Noradrenergic mechanisms in Parkinson's disease,” Trends in Pharmacological Sciences, vol. 14, no. 2, pp. 33–34, 1993. View at Publisher · View at Google Scholar · View at Scopus
  28. K. S. Rommelfanger and D. Weinshenker, “Norepinephrine: the redheaded stepchild of Parkinson's disease,” Biochemical Pharmacology, vol. 74, no. 2, pp. 177–190, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chui, “Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases,” Archives of Neurology, vol. 60, no. 3, pp. 337–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. Espay, P. A. Lewitt, and H. Kaufmann, “Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement,” Movement Disorders, vol. 29, no. 14, pp. 1710–1719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Halliday, “An evidence base for noradrenergic deficits in Parkinson's disease,” Movement Disorders, vol. 27, no. 13, pp. 1589–1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Pertovaara, “Noradrenergic pain modulation,” Progress in Neurobiology, vol. 80, no. 2, pp. 53–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Pertovaara, “The noradrenergic pain regulation system: a potential target for pain therapy,” European Journal of Pharmacology, vol. 716, no. 1–3, pp. 2–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. Jones, “Descending noradrenergic influences on pain,” Progress in Brain Research, vol. 88, pp. 381–394, 1991. View at Publisher · View at Google Scholar · View at Scopus
  35. D.-H. Roh, H.-W. Kim, S.-Y. Yoon et al., “Intrathecal clonidine suppresses phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit in spinal dorsal horn neurons of rats with neuropathic pain,” Anesthesia and Analgesia, vol. 107, no. 2, pp. 693–700, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Hughes, L. Hickey, L. F. Donaldson, B. M. Lumb, and A. E. Pickering, “Intrathecal reboxetine suppresses evoked and ongoing neuropathic pain behaviours by restoring spinal noradrenergic inhibitory tone,” Pain, vol. 156, no. 2, pp. 328–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Obata, D. Conklin, and J. C. Eisenach, “Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats,” Pain, vol. 113, no. 3, pp. 271–276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Zimmermann, “Ethical guidelines for investigations of experimental pain in conscious animals,” Pain, vol. 16, no. 2, pp. 109–110, 1983. View at Publisher · View at Google Scholar · View at Scopus
  39. A. L. Eagle, O. O. Olumolade, and H. Otani, “Partial dopaminergic denervation-induced impairment in stimulus discrimination acquisition in parkinsonian rats: a model for early Parkinson's disease,” Neuroscience Research, vol. 92, pp. 71–79, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Kudo, T. Kushikata, M. Kudo, T. Kudo, and K. Hirota, “A central neuropathic pain model by DSP-4 induced lesion of noradrenergic neurons: preliminary report,” Neuroscience Letters, vol. 481, no. 2, pp. 102–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Kudo, T. Kushikata, M. Kudo, T. Kudo, and K. Hirota, “Antinociceptive effects of neurotropin in a rat model of central neuropathic pain: DSP-4 induced noradrenergic lesion,” Neuroscience Letters, vol. 503, no. 1, pp. 20–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Soria-Fregozo, M. E. Flores-Soto, M. I. Pérez-Vega, and A. Feria-Velasco, “5-HT denervation of the adult rat prefrontal cortex induces changes in the expression of α4 and α7 nicotinic acetylcholine receptor subtypes,” Neurología, vol. 28, no. 4, pp. 212–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Ciobica, L. Hritcu, M. Padurariu, R. Dobrin, and V. Bild, “Effects of serotonin depletion on behavior and neuronal oxidative stress status in rat: relevance for anxiety and affective disorders,” Advances in Medical Sciences, vol. 55, no. 2, pp. 289–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88, 1988. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Xiao, A. Boroujerdi, G. J. Bennett, and Z. D. Luo, “Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit,” Neuroscience, vol. 144, no. 2, pp. 714–720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. C. R. McNamara, J. Mandel-Brehm, D. M. Bautista et al., “TRPA1 mediates formalin-induced pain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 33, pp. 13525–13530, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. N. R. Rustay, D. Wahlsten, and J. C. Crabbe, “Influence of task parameters on rotarod performance and sensitivity to ethanol in mice,” Behavioural Brain Research, vol. 141, no. 2, pp. 237–249, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. W. Dieb, O. Ouachikh, F. Durif, and A. Hafidi, “Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia,” Brain and Behavior, vol. 4, no. 3, pp. 368–380, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Zengin-Toktas, J. Ferrier, F. Durif, P.-M. Llorca, and N. Authier, “Bilateral lesions of the nigrostriatal pathways are associated with chronic mechanical pain hypersensitivity in rats,” Neuroscience Research, vol. 76, no. 4, pp. 261–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Mylius, J. Brebbermann, H. Dohmann, I. Engau, W. H. Oertel, and J. C. Möller, “Pain sensitivity and clinical progression in Parkinson's disease,” Movement Disorders, vol. 26, no. 12, pp. 2220–2225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. F.-X. Zhong, X.-Q. Ji, and K. Tsou, “Intrathecal DSP4 selectively depletes spinal noradrenaline and attenuates morphine analgesia,” European Journal of Pharmacology, vol. 116, no. 3, pp. 327–330, 1985. View at Publisher · View at Google Scholar · View at Scopus
  52. H. Kaufmann, “L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience,” Clinical Autonomic Research, vol. 18, supplement 1, pp. 19–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. B. Dehay and E. Bezard, “New animal models of Parkinson's disease,” Movement Disorders, vol. 26, no. 7, pp. 1198–1205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Park, C.-S. Lim, H. Seo et al., “Pain perception in acute model mice of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),” Molecular Pain, vol. 11, no. 1, article 28, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. L. E. Gee, N. Chen, A. Ramirez-Zamora, D. S. Shin, and J. G. Pilitsis, “The effects of subthalamic deep brain stimulation on mechanical and thermal thresholds in 6OHDA-lesioned rats,” European Journal of Neuroscience, vol. 42, no. 4, pp. 2061–2069, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Chen, J. Liu, Q. J. Zhang et al., “Alterations of emotion, cognition and firing activity of the basolateral nucleus of the amygdala after partial bilateral lesions of the nigrostriatal pathway in rats,” Brain Research Bulletin, vol. 85, no. 6, pp. 329–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Cannon and J. T. Greenamyre, “Neurotoxic in vivo models of Parkinson's disease recent advances,” Progress in Brain Research, vol. 184, pp. 17–33, 2010. View at Publisher · View at Google Scholar
  58. B. Scatton, T. Dennis, R. L'Heureux, J.-C. Monfort, C. Duyckaerts, and F. Javoy-Agid, “Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients,” Brain Research, vol. 380, no. 1, pp. 181–185, 1986. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Pintor, E. Baillès, F. Valldeoriola, E. Tolosa, M. J. Martí, and J. de Pablo, “Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode,” General Hospital Psychiatry, vol. 28, no. 1, pp. 59–64, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. W. Guo, K. Miyoshi, R. Dubner et al., “Spinal 5-HT3 receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glial signaling cascade,” Molecular Pain, vol. 10, article 35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Hoshino, H. Obata, and S. Saito, “Antihyperalgesic effect of duloxetine and amitriptyline in rats after peripheral nerve injury: influence of descending noradrenergic plasticity,” Neuroscience Letters, vol. 602, pp. 62–67, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Kinoshita, Y. Takahashi, A. M. Watabe, K. Utsunomiya, and F. Kato, “Impaired noradrenaline homeostasis in rats with painful diabetic neuropathy as a target of duloxetine analgesia,” Molecular Pain, vol. 9, no. 1, article 59, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Brefel-Courbon, P. Payoux, C. Thalamas et al., “Effects of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study,” Movement Disorders, vol. 20, no. 12, pp. 1557–1563, 2005. View at Publisher · View at Google Scholar · View at Scopus
  64. P. B. Molinoff and J. Axelrod, “Biochemistry of catecholamines,” Annual Review of Biochemistry, vol. 40, pp. 465–500, 1971. View at Google Scholar · View at Scopus
  65. W. Maruyama, M. Naoi, and H. Narabayashi, “The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients,” Journal of the Neurological Sciences, vol. 139, no. 1, pp. 141–148, 1996. View at Publisher · View at Google Scholar · View at Scopus